Wall Street analysts expect Summit Therapeutics to report a Q3 2026 consensus revenue of $0.11 million and a net loss of $0.28 per share, while the stock currently trades at $16.33 compared to an average price target of $30.28.
Investors are primarily watching for regulatory progress on ivonescimab, the company's lead oncology candidate, ahead of its critical November 14 FDA PDUFA decision date.
The company recently strengthened its balance sheet with a $2 billion strategic investment from AstraZeneca, significantly extending its cash runway for late-stage clinical trials. Markets will also look for management's updates on patient enrollment in the HARMONi-3 study and broader commercialization timelines for solid tumor indications.